Info@surgeryconf2025.org +91 9732 300 0007

Protocol Summary

This study aims to evaluate the efficacy and safety of Drug X compared to placebo in patients with Condition Y. The primary endpoint is the change in symptom severity score from baseline to week 12. Secondary endpoints include changes in quality of life and adverse event rates.

Objectives

Primary Objective: To determine the superiority of Drug X over placebo in reducing symptom severity in patients with Condition Y. Secondary Objectives: To assess the impact of Drug X on patients' quality of life and to evaluate the safety profile of Drug X.

Study Design

This is a randomized, double-blind, placebo-controlled, parallel-group study. Eligible patients will be randomized in a 1:1 ratio to receive either Drug X or placebo for 12 weeks. Assessments will be conducted at baseline, week 4, week 8, and week 12.

Enterprise -grade clinical research
management platform trusted by
leading pharmaceutical companies and
CRO’s worldwide.

Platform
Compliance
Support
Follow Us On:

@2025 CRO Platform .All rights Reserved. Privacy Policy . Terms of Service . Cookie Policy

Validated & secure